TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30679439

Group type: EXPERIMENTAL
Intervention: Early limited ART (part of the CHER trial)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1
Study: 26934057

Group type: EXPERIMENTAL
Intervention: Cuff inflation at 140 mmHg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cuff inflation at 180 mmHg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cuff deflation after occlusion
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cuff inflation pressures (140, 160, 180 mmHg)
Number of subjects: 6
Study: 24531357

Group type: EXPERIMENTAL
Intervention: Semitendinosus autograft (ST)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Semitendinosus + gracilis (ST/G)
Number of subjects: 19
Study: 23725526

Group type: EXPERIMENTAL
Intervention: 7.5 g/day of dietary fiber for 12 weeks
Number of subjects: 30
Study: 22050131

Group type: COMPARATOR
Intervention: HOT (40.2 ± 0.3 °C)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: MOD (20.4 ± 0.7 °C)
Number of subjects: 11
Study: 19692210

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg i.v. once daily
Number of subjects: 364

Group type: COMPARATOR
Intervention: Ceftriaxone 2 g i.v. once daily plus Metronidazole 500 mg i.v. twice daily
Number of subjects: 364
Study: 16530145

Group type: EXPERIMENTAL
Intervention: Primary care medical record
Number of subjects: 443

Group type: COMPARATOR
Intervention: Maternal interview
Number of subjects: 443
Study: 15600227

Group type: EXPERIMENTAL
Intervention: Combined (Medication + CBT for 10 weeks)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Overlapping (Medication for 5 weeks, CBT introduced at week 4, medication withdrawal after 5 weeks)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Medication -> CBT (Medication alone for 5 weeks, then CBT alone for 5 weeks)
Number of subjects: 6
Study: 11725446

Group type: EXPERIMENTAL
Intervention: Teaching booklet with humor
Number of subjects: 50

Group type: COMPARATOR
Intervention: Teaching booklet without humor
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups (with and without humor)
Number of subjects: 50
Study: 9652561

Group type: EXPERIMENTAL
Intervention: RRV-TV (titre 4x10(5) plaque-forming units)
Number of subjects: 2398

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2398
Study: 8215749

Group type: EXPERIMENTAL
Intervention: Nizatidine, 150 mg twice daily
Number of subjects: 496

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 496

Group type: COMPARATOR
Intervention: Nizatidine and Placebo
Number of subjects: 496
Study: 3300761

Group type: EXPERIMENTAL
Intervention: Melphalan treatment
Number of subjects: 648

Group type: COMPARATOR
Intervention: Cyclophosphamide treatment
Number of subjects: 648
Study: 30875336

Group type: EXPERIMENTAL
Intervention: PET-CTB protocol (N=100)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Standard protocol (N=161)
Number of subjects: 217
Study: 28954640

Group type: EXPERIMENTAL
Intervention: beta2-1 fructan (3x5 g/d for 28 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: maltodextrin (3x5 g/d for 28 days)
Number of subjects: 30
Study: 25082070

Group type: EXPERIMENTAL
Intervention: Office hysteroscopy prior to ICSI
Number of subjects: 193

Group type: COMPARATOR
Intervention: ICSI alone (without hysteroscopy)
Number of subjects: 193
Study: 22936530

Group type: EXPERIMENTAL
Intervention: Kansas Dementia Crisis Bridge Project intervention
Number of subjects: 0
Study: 21694627

Group type: COMPARATOR
Intervention: Methylphenidate (40 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Tianeptine (75 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 18266566

Group type: EXPERIMENTAL
Intervention: Preoperative volume replacement
Number of subjects: 210

Group type: COMPARATOR
Intervention: Intraoperative volume replacement
Number of subjects: 210
Study: 16931978

Group type: EXPERIMENTAL
Intervention: Endobronchial blocker
Number of subjects: 60

Group type: COMPARATOR
Intervention: Double-lumen tube
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 12937193

Group type: EXPERIMENTAL
Intervention: Alcohol (low blood alcohol concentration, around half the UK legal driving limit)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sleep restriction
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combined alcohol and sleep restriction
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (no alcohol)
Number of subjects: 12
Study: 10937515

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 45
Study: 8606273

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 38
Study: 1290169

Group type: EXPERIMENTAL
Intervention: Antithrombin III (ATIII) replacement therapy before the induction of anaesthesia and throughout surgery
Number of subjects: 29

Group type: COMPARATOR
Intervention: No Antithrombin III replacement therapy
Number of subjects: 29
Study: 6237663

Group type: EXPERIMENTAL
Intervention: Group H received alcuronium and were ventilated artificially using 0.5% halothane and nitrous oxide in oxygen
Number of subjects: 56

Group type: COMPARATOR
Intervention: Group E breathed spontaneously a mixture of enflurane and nitrous oxide in oxygen
Number of subjects: 56
Study: 30673543

Group type: EXPERIMENTAL
Intervention: Levodopa (100 mg three times per day) in combination with carbidopa (25 mg three times per day) for 80 weeks
Number of subjects: 445

Group type: COMPARATOR
Intervention: Placebo for 40 weeks followed by levodopa in combination with carbidopa for 40 weeks
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Levodopa (early-start group)
Number of subjects: 445

Group type: COMPARATOR
Intervention: Placebo (delayed-start group)
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Levodopa in combination with carbidopa
Number of subjects: 445
Study: 29494727

Group type: EXPERIMENTAL
Intervention: Ranibizumab monotherapy
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Ranibizumab and laser combination therapy
Number of subjects: 240

Group type: COMPARATOR
Intervention: Laser monotherapy
Number of subjects: 240
Study: 25217447

Group type: EXPERIMENTAL
Intervention: Arousing picture stimuli
Number of subjects: 95

Group type: COMPARATOR
Intervention: Non-arousing picture stimuli
Number of subjects: 95
Study: 23990646

Group type: EXPERIMENTAL
Intervention: Behavioral activation treatment for depression (BATD)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Problem-solving therapy (PST)
Number of subjects: 80
Study: 21415158

Group type: EXPERIMENTAL
Intervention: Copeptin levels in the highest quartile (>122 pmol/L)
Number of subjects: 1241
Study: 19480671

Group type: EXPERIMENTAL
Intervention: group‐based lifestyle rehabilitation programme
Number of subjects: 180

Group type: COMPARATOR
Intervention: conventional individual counselling
Number of subjects: 180
Study: 17550216

Group type: EXPERIMENTAL
Intervention: Insulin glargine (GLAR; n=74)
Number of subjects: 142

Group type: COMPARATOR
Intervention: NPH/semilente insulin (NPH; n=68)
Number of subjects: 142
Study: 14504683

Group type: EXPERIMENTAL
Intervention: Baclofen (0, 10, 20 and 30 mg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Intranasal cocaine (45 mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (4 mg)
Number of subjects: 7
Study: 11816230

Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study: 9731558

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 9071430

Group type: EXPERIMENTAL
Intervention: Dronabinol 2.5 mg twice/day (D)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Megestrol acetate 750 mg/day (M750)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Megestrol acetate 750 mg/day + dronabinol 2.5 mg twice/day (M750+D)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Megestrol acetate 250 mg/day + dronabinol 2.5 mg twice/day (M250+D)
Number of subjects: 52

Group type: COMPARATOR
Intervention: All treatment arms
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Megestrol acetate (M750)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Dronabinol
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Megestrol acetate
Number of subjects: 52
Study: 1685532

Group type: EXPERIMENTAL
Intervention: 0.125% intraocular dapiprazole
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 0.25% intraocular dapiprazole
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 0.5% intraocular dapiprazole
Number of subjects: 120

Group type: COMPARATOR
Intervention: Balanced salt solution (control)
Number of subjects: 120
Study: 7069205

Group type: EXPERIMENTAL
Intervention: delta MTCI
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Change in malar temperature
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Peak malar temperature
Number of subjects: 162
Study: 30790061

Group type: EXPERIMENTAL
Intervention: Rifampicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probe drugs and endogenous substrates
Number of subjects: 0
Study: 29606379

Group type: EXPERIMENTAL
Intervention: Panretinal photocoagulation (PRP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (IVR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early vitrectomy (PPV)
Number of subjects: 0
Study: 26836729

Group type: EXPERIMENTAL
Intervention: Subcutaneous dupilumab (600 mg loading dose followed by 300 mg weekly)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Subcutaneous dupilumab
Number of subjects: 60
Study: 22753280

Group type: EXPERIMENTAL
Intervention: Quetiapine XR 150 mg/day
Number of subjects: 968

Group type: EXPERIMENTAL
Intervention: Quetiapine XR 300 mg/day
Number of subjects: 968

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 968
Study: 19508542

Group type: EXPERIMENTAL
Intervention: Stapled haemorrhoidopexy (SH)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Rubber band ligation (RBL)
Number of subjects: 60
Study: 18592619

Group type: EXPERIMENTAL
Intervention: Proactive tacrolimus 0.1% ointment applied twice weekly
Number of subjects: 257

Group type: COMPARATOR
Intervention: Vehicle ointment applied twice weekly
Number of subjects: 257
Study: 15714897

Group type: EXPERIMENTAL
Intervention: Children with chromosome 22q11.2 deletion syndrome
Number of subjects: 0

Group type: COMPARATOR
Intervention: Typically developing controls
Number of subjects: 0
Study: 12106617

Group type: EXPERIMENTAL
Intervention: Immediate education program consisting of three group sessions delivered by trained educators.
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control group (6-month waiting list).
Number of subjects: 131
Study: 9990217

Group type: EXPERIMENTAL
Intervention: Fentanyl 4 micrograms.kg‐1
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Fentanyl 2 micrograms.kg‐1
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Pentazocine 0.5 mg.kg‐1
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Buprenorphine 5 micrograms.kg‐1
Number of subjects: 70

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 70
Study: 7939455

Group type: EXPERIMENTAL
Intervention: Biofeedback treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no biofeedback)
Number of subjects: 20
Study: 2464358

Group type: EXPERIMENTAL
Intervention: CAF (cyclophosphamide, doxorubicin, 5‐fluorouracil)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CMF (cyclophosphamide, methotrexate, 5‐fluorouracil)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard chemotherapy (not specified)
Number of subjects: 0
Study: 29587625

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 28
Study: 26670614

Group type: EXPERIMENTAL
Intervention: Pregabalin (75 mg qid to 300 mg bid)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 24409833

Group type: EXPERIMENTAL
Intervention: Q-switched Nd:YAG laser
Number of subjects: 15

Group type: COMPARATOR
Intervention: Er:YAG micropeel
Number of subjects: 15
Study: 22489439

Group type: EXPERIMENTAL
Intervention: Organ donation intervention at DMV offices
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care at DMV offices
Number of subjects: 30
Study: 20555274

Group type: EXPERIMENTAL
Intervention: Unstable resistance training
Number of subjects: 18

Group type: COMPARATOR
Intervention: Stable resistance training
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Overall training (both groups)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Stable isometric chest press
Number of subjects: 18
Study: 18295470

Group type: EXPERIMENTAL
Intervention: Intermittent labor epidural analgesia (ILEA)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Continuous labor epidural analgesia (CLEA)
Number of subjects: 92
Study: 16417778

Group type: EXPERIMENTAL
Intervention: YBK Tablets (40 mg, three times per day)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Leucogen Tablets (20 mg, three times per day)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo (Vitamin C tablets 100 mg, three times per day)
Number of subjects: 105
Study: 12708879

Group type: EXPERIMENTAL
Intervention: Perindopril 2mg/Indapamide 0.625 mg
Number of subjects: 471

Group type: COMPARATOR
Intervention: Atenolol 50mg
Number of subjects: 471
Study: 10690162

Group type: EXPERIMENTAL
Intervention: Palm oil (PO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lard (LD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Puff-pastry margarine (PPM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Obese women (control group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal-weight women (control group)
Number of subjects: 0
Study: 8767824

Group type: EXPERIMENTAL
Intervention: Single-dose fluconazole (150 mg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 7-day fluconazole treatment (daily 50 mg)
Number of subjects: 22
Study: 1616165

Group type: EXPERIMENTAL
Intervention: Clonidine (150 micrograms) with 40 mL of 1% lidocaine
Number of subjects: 33

Group type: COMPARATOR
Intervention: Epinephrine (200 micrograms) with 40 mL of 1% lidocaine
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Clonidine (150 micrograms)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Epinephrine (200 micrograms)
Number of subjects: 33
Study: 6589042

Group type: EXPERIMENTAL
Intervention: Early intensification therapy with two doses of asparaginase during induction therapy
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Delayed intensification therapy with four doses of asparaginase and cytarabine after remission induction
Number of subjects: 277

Group type: COMPARATOR
Intervention: Late intensification therapy added to maintenance protocol
Number of subjects: 277
Study: 31683942

Group type: EXPERIMENTAL
Intervention: Menu with allergens listed
Number of subjects: 600

Group type: COMPARATOR
Intervention: Menu without allergens listed
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: High Food Neophobia (FN)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: High FN respondents
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Allergen content and perceived lack of healthiness
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Food neophobia
Number of subjects: 600
Study: 29901865

Group type: EXPERIMENTAL
Intervention: Olfactory training with budesonide irrigations
Number of subjects: 138

Group type: COMPARATOR
Intervention: Olfactory training with saline irrigations
Number of subjects: 138
Study: 27423162

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) self-help workbook
Number of subjects: 503

Group type: COMPARATOR
Intervention: Wait-list condition
Number of subjects: 503
Study: 24326811

Group type: EXPERIMENTAL
Intervention: Diode laser treatment (980 nm wavelength) after biomechanical preparation in Group A
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional method using sodium hypochlorite and hydrogen peroxide in Group B
Number of subjects: 60
Study: 22333330

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 727

Group type: EXPERIMENTAL
Intervention: Feedback only (FB)
Number of subjects: 727

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing with Feedback (MIFB)
Number of subjects: 727

Group type: COMPARATOR
Intervention: Assessment Only (AO)
Number of subjects: 727
Study: 20153900

Group type: EXPERIMENTAL
Intervention: 600 IU of natural-source vitamin E on alternate days
Number of subjects: 39876

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39876
Study: 17868455

Group type: EXPERIMENTAL
Intervention: OROS-MPH
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: IR-MPH (tid)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 269
Study: 15605279

Group type: COMPARATOR
Intervention: Blackcurrant anthocyanin (BCA) 17 mg kg(‐1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Blackcurrant anthocyanin (BCA) 7.7 mg kg(‐1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (isoenergetic sugar)
Number of subjects: 20
Study: 11796166

Group type: EXPERIMENTAL
Intervention: Cranial electrostimulation (CES)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 10219807

Group type: EXPERIMENTAL
Intervention: Chemotherapy (cisplatin and 5‐fluorouracil) alternated with radiotherapy (60 Gy/30 fractions)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Radiotherapy treatment
Number of subjects: 115
Study: 8587999

Group type: EXPERIMENTAL
Intervention: Partial syndrome (PS) eating disorders
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Full syndrome (FS) eating disorders (anorexia nervosa or bulimia nervosa)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Normal controls (NC)
Number of subjects: 138
Study: 2082424

Group type: EXPERIMENTAL
Intervention: Four posterior composite resins
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Scanning electron microscopic evaluation
Number of subjects: 77
Study: 394062

Group type: EXPERIMENTAL
Intervention: Topical timolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral timolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical timolol alone
Number of subjects: 0
Study: 31154316

Group type: EXPERIMENTAL
Intervention: LEGO-based therapy with usual care
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 240
Study: 27114108

Group type: EXPERIMENTAL
Intervention: Postoperative physical health-related quality of life
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Preoperative weight loss
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Postoperative mental health-related quality of life
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Preoperative health-related quality of life
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Sarcopenia
Number of subjects: 447
Study: 26007264

Group type: EXPERIMENTAL
Intervention: Isosorbide Mononitrate (IMN) 40 mg tablet vaginally every 6 hours for a maximum of 4 doses
Number of subjects: 200

Group type: COMPARATOR
Intervention: Misoprostol 50 μg tablet vaginally every 6 hours for a maximum of 4 doses
Number of subjects: 200
Study: 24012648

Group type: EXPERIMENTAL
Intervention: Snus (4mg of nicotine)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo snus
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo alcohol
Number of subjects: 35
Study: 21443321

Group type: EXPERIMENTAL
Intervention: CBT plus supportive listening (n = 40)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: CBT plus interpersonal and emotional processing therapy (n = 43)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 83
Study: 19653755

Group type: EXPERIMENTAL
Intervention: Manual reaction times
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Saccadic reaction times
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Event-related potential latencies
Number of subjects: 0
Study: 16829487

Group type: EXPERIMENTAL
Intervention: Reduced available processing resources at encoding in younger adults (Experiments 1 and 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased available processing resources in both age groups (Experiments 2 and 3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-recall test asking participants to report items thought of but not recalled
Number of subjects: 0
Study: 15104642

Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution (ANH)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 42

Group type: COMPARATOR
Intervention: Another blood conservation method
Number of subjects: 42
Study: 11251875

Group type: EXPERIMENTAL
Intervention: Continence Efficacy Intervention Program (CEIP)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional intervention
Number of subjects: 48
Study: 9287253

Group type: EXPERIMENTAL
Intervention: Relaxation and EMG biofeedback training (N = 30)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Assessment only control group (N = 14)
Number of subjects: 44
Study: 7683553

Group type: EXPERIMENTAL
Intervention: Highly fluorescent reticulocyte (HFR) counts after autologous BMT
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Highly fluorescent reticulocyte (HFR) counts after allogeneic BMT
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Highly fluorescent reticulocyte (HFR) counts
Number of subjects: 42
Study: 3333522

Group type: EXPERIMENTAL
Intervention: Reduced alcohol consumption (Group A)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Usual alcohol consumption (Group B)
Number of subjects: 49
Study: 29126601

Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation (ORIF) with locked plating
Number of subjects: 0

Group type: COMPARATOR
Intervention: ORIF with cable plating ± cortical strut allograft
Number of subjects: 0
Study: 26916794

Group type: EXPERIMENTAL
Intervention: rosuvastatin 20 mg daily
Number of subjects: 17082

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17082
Study: 25816542

Group type: EXPERIMENTAL
Intervention: Intramuscular vitamin A 5,000 IU 3 times/week for four weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 80
Study: 22218160

Group type: EXPERIMENTAL
Intervention: Increased intake of oily fish (2 portions of salmon per week providing 3.45 g EPA plus DHA) from 20 weeks gestation until delivery
Number of subjects: 123

Group type: COMPARATOR
Intervention: Habitual diet low in oily fish (control group)
Number of subjects: 123